FDA Moves To Guard Against Abuse Of ‘Orphan Drug’ Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
The independent source for health policy research, polling, and news.
2,441 - 2,460 of 3,946 Results
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of “orphan drugs” while closing a loophole that allowed drugmakers to skip pediatric testing.
The Senate health committee is putting aside partisan bickering this month to seek a legislative remedy to a possible spike in Obamacare premiums this fall.
To strengthen your core knowledge of health care policy, it helps to be a regular reader of Kaiser Health News. Here's a pop quiz to gauge what you have learned.
Gobbling up doctors’ independent practices is lucrative for hospital systems — but not necessarily a good deal for the physicians or consumers, critics say. Northern California is a case in point.
This immunization may mark a shift among some vaccine makers to higher-priced, “niche” preventives that protect against very specific and sometimes rare illnesses.
State leaders tell senators that federal dollars are needed this fall to keep insurers participating in Obamacare next year and prevent big hikes in premiums.
Hospice care often prompts fear and misunderstanding, but the services provided can lead to less pain and trauma at the end of life.
The fate of the Affordable Care Act’s individual insurance marketplaces remains in play as state insurance commissioners take a central role in the debate.
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.
No longer able to get exemptions for personal beliefs in California, parents opposed to inoculations seem to be obtaining medical exemptions for their children, according to a new study.
Innate Immunotherapeutics, the Australian biotech firm whose largest shareholder is Buffalo, N.Y.-area congressman Chris Collins, said it expects to close after its multiple sclerosis drug failed in trials.
After a Kaiser Health News report on an offshore herpes vaccine trial that skirted FDA regulations, St. Kitts and Nevis officials claim they had no knowledge of the testing. An investigation is underway.
The USA's first approved gene therapy — to be used to fight leukemia that resists standard therapies — will cost $475,000 for a one-time treatment.
In this Facebook Live, KHN’s Julie Appleby talks with Stephanie Stapleton and answers readers’ questions about the prescription drug pricing pipeline and the industry stakeholders who have a role in what you pay.
Painkillers were never designed to be used over the long term, says the head of the Mayo Clinic’s pain rehabilitation center. Instead, patients should try other approaches, including relaxation therapies. But getting insurers to cover them might take coaxing.
Prominent businessmen and an American university supported offshore testing of an experimental vaccine.
State lawmakers in California have an answer: legislation that would require your new insurer to keep paying for your current doctors even if they’re not in the network.
In this episode of “What the Health?” Julie Rovner of Kaiser Health News, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Margot Sanger-Katz of The New York Times discuss the continuing efforts in Congress to “repeal and replace” the Affordable Care Act, upcoming open enrollment for individual insurance and Congress’ long health care to-do list for September.
In this episode of “What the Health?” Mary Agnes Carey of Kaiser Health News, Sarah Karlin-Smith of Politico, Margot Sanger-Katz of The New York Times and Julie Appleby of Kaiser Health News discuss the recent extension of cost-sharing subsidies for millions of low-income beneficiaries on the Affordable Care Act’s marketplaces and the state of play on Capitol Hill and in the states concerning initiatives to lower prescription drug costs.
Growing numbers of physicians say they support a single-payer health care system, a 180-degree turn in opinion over a decade.
© 2026 KFF